Literature DB >> 30287662

Reprogramming normal human epithelial tissues to a common, lethal neuroendocrine cancer lineage.

Jung Wook Park1, John K Lee2, Katherine M Sheu3, Liang Wang1, Nikolas G Balanis3, Kim Nguyen4, Bryan A Smith1, Chen Cheng5, Brandon L Tsai1, Donghui Cheng1, Jiaoti Huang6, Siavash K Kurdistani5,7,8,9, Thomas G Graeber10,7,8,9,11, Owen N Witte12,3,7,8,9.   

Abstract

The use of potent therapies inhibiting critical oncogenic pathways active in epithelial cancers has led to multiple resistance mechanisms, including the development of highly aggressive, small cell neuroendocrine carcinoma (SCNC). SCNC patients have a dismal prognosis due in part to a limited understanding of the molecular mechanisms driving this malignancy and the lack of effective treatments. Here, we demonstrate that a common set of defined oncogenic drivers reproducibly reprograms normal human prostate and lung epithelial cells to small cell prostate cancer (SCPC) and small cell lung cancer (SCLC), respectively. We identify shared active transcription factor binding regions in the reprogrammed prostate and lung SCNCs by integrative analyses of epigenetic and transcriptional landscapes. These results suggest that neuroendocrine cancers arising from distinct epithelial tissues may share common vulnerabilities that could be exploited for the development of drugs targeting SCNCs.
Copyright © 2018 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30287662      PMCID: PMC6414229          DOI: 10.1126/science.aat5749

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   47.728


  47 in total

Review 1.  The Ets-transcription factor family in embryonic development: lessons from the amphibian and bird.

Authors:  P Remy; M Baltzinger
Journal:  Oncogene       Date:  2000-12-18       Impact factor: 9.867

2.  The program of androgen-responsive genes in neoplastic prostate epithelium.

Authors:  Peter S Nelson; Nigel Clegg; Hugh Arnold; Camari Ferguson; Michael Bonham; James White; Leroy Hood; Biaoyang Lin
Journal:  Proc Natl Acad Sci U S A       Date:  2002-08-16       Impact factor: 11.205

3.  Identification of genes targeted by the androgen and PKA signaling pathways in prostate cancer cells.

Authors:  G Wang; S J M Jones; M A Marra; M D Sadar
Journal:  Oncogene       Date:  2006-06-05       Impact factor: 9.867

Review 4.  Humanized mice in translational biomedical research.

Authors:  Leonard D Shultz; Fumihiko Ishikawa; Dale L Greiner
Journal:  Nat Rev Immunol       Date:  2007-02       Impact factor: 53.106

5.  ASH1 gene is a specific therapeutic target for lung cancers with neuroendocrine features.

Authors:  Hirotaka Osada; Yoshio Tatematsu; Yasushi Yatabe; Yoshitsugu Horio; Takashi Takahashi
Journal:  Cancer Res       Date:  2005-12-01       Impact factor: 12.701

6.  The Sca-1 cell surface marker enriches for a prostate-regenerating cell subpopulation that can initiate prostate tumorigenesis.

Authors:  Li Xin; Devon A Lawson; Owen N Witte
Journal:  Proc Natl Acad Sci U S A       Date:  2005-04-28       Impact factor: 11.205

7.  Molecular characterization of TMPRSS2-ERG gene fusion in the NCI-H660 prostate cancer cell line: a new perspective for an old model.

Authors:  Kirsten D Mertz; Sunita R Setlur; Saravana M Dhanasekaran; Francesca Demichelis; Sven Perner; Scott Tomlins; Joëlle Tchinda; Bharathi Laxman; Robert L Vessella; Rameen Beroukhim; Charles Lee; Arul M Chinnaiyan; Mark A Rubin
Journal:  Neoplasia       Date:  2007-03       Impact factor: 5.715

8.  Up-regulation of Bcl-2 is required for the progression of prostate cancer cells from an androgen-dependent to an androgen-independent growth stage.

Authors:  Yuting Lin; Junichi Fukuchi; Richard A Hiipakka; John M Kokontis; Jialing Xiang
Journal:  Cell Res       Date:  2007-06       Impact factor: 25.617

9.  Thyroid transcription factor-1 is expressed in extrapulmonary small cell carcinomas but not in other extrapulmonary neuroendocrine tumors.

Authors:  S N Agoff; L W Lamps; A T Philip; M B Amin; R A Schmidt; L D True; A L Folpe
Journal:  Mod Pathol       Date:  2000-03       Impact factor: 7.842

10.  Distinction of pulmonary small cell carcinoma from poorly differentiated squamous cell carcinoma: an immunohistochemical approach.

Authors:  Hong Zhang; Jing Liu; Philip T Cagle; Timothy C Allen; Alvaro C Laga; Dani S Zander
Journal:  Mod Pathol       Date:  2005-01       Impact factor: 7.842

View more
  95 in total

1.  Molecular profiling stratifies diverse phenotypes of treatment-refractory metastatic castration-resistant prostate cancer.

Authors:  Mark P Labrecque; Ilsa M Coleman; Lisha G Brown; Lawrence D True; Lori Kollath; Bryce Lakely; Holly M Nguyen; Yu C Yang; Rui M Gil da Costa; Arja Kaipainen; Roger Coleman; Celestia S Higano; Evan Y Yu; Heather H Cheng; Elahe A Mostaghel; Bruce Montgomery; Michael T Schweizer; Andrew C Hsieh; Daniel W Lin; Eva Corey; Peter S Nelson; Colm Morrissey
Journal:  J Clin Invest       Date:  2019-07-30       Impact factor: 14.808

Review 2.  Cell Cycle and Beyond: Exploiting New RB1 Controlled Mechanisms for Cancer Therapy.

Authors:  Erik S Knudsen; Steven C Pruitt; Pamela A Hershberger; Agnieszka K Witkiewicz; David W Goodrich
Journal:  Trends Cancer       Date:  2019-04-30

3.  Predicting clinical outcome of therapy-resistant prostate cancer.

Authors:  Xin Ma; Jiaoti Huang
Journal:  Proc Natl Acad Sci U S A       Date:  2019-05-21       Impact factor: 11.205

4.  LIN28B promotes the development of neuroendocrine prostate cancer.

Authors:  Jessica Lovnicki; Yu Gan; Tingting Feng; Yinan Li; Ning Xie; Chia-Hao Ho; Ahn R Lee; Xufeng Chen; Lucia Nappi; Bo Han; Ladan Fazli; Jiaoti Huang; Martin E Gleave; Xuesen Dong
Journal:  J Clin Invest       Date:  2020-10-01       Impact factor: 14.808

5.  Pan-cancer Convergence to a Small-Cell Neuroendocrine Phenotype that Shares Susceptibilities with Hematological Malignancies.

Authors:  Nikolas G Balanis; Katherine M Sheu; Favour N Esedebe; Saahil J Patel; Bryan A Smith; Jung Wook Park; Salwan Alhani; Brigitte N Gomperts; Jiaoti Huang; Owen N Witte; Thomas G Graeber
Journal:  Cancer Cell       Date:  2019-07-08       Impact factor: 31.743

6.  Circulating Tumor DNA Profiling in Small-Cell Lung Cancer Identifies Potentially Targetable Alterations.

Authors:  Siddhartha Devarakonda; Sumithra Sankararaman; Brett H Herzog; Kathryn A Gold; Saiama N Waqar; Jeffrey P Ward; Victoria M Raymond; Richard B Lanman; Aadel A Chaudhuri; Taofeek K Owonikoko; Bob T Li; John T Poirier; Charles M Rudin; Ramaswamy Govindan; Daniel Morgensztern
Journal:  Clin Cancer Res       Date:  2019-07-12       Impact factor: 12.531

7.  Targeting RET Kinase in Neuroendocrine Prostate Cancer.

Authors:  Halena R VanDeusen; Johnny R Ramroop; Katherine L Morel; Song Yi Bae; Anjali V Sheahan; Zoi Sychev; Nathan A Lau; Larry C Cheng; Victor M Tan; Zhen Li; Ashley Petersen; John K Lee; Jung Wook Park; Rendong Yang; Justin H Hwang; Ilsa Coleman; Owen N Witte; Colm Morrissey; Eva Corey; Peter S Nelson; Leigh Ellis; Justin M Drake
Journal:  Mol Cancer Res       Date:  2020-05-27       Impact factor: 5.852

8.  Circulating tumor DNA profile recognizes transformation to castration-resistant neuroendocrine prostate cancer.

Authors:  Himisha Beltran; Alessandro Romanel; Vincenza Conteduca; Nicola Casiraghi; Michael Sigouros; Gian Marco Franceschini; Francesco Orlando; Tarcisio Fedrizzi; Sheng-Yu Ku; Emma Dann; Alicia Alonso; Juan Miguel Mosquera; Andrea Sboner; Jenny Xiang; Olivier Elemento; David M Nanus; Scott T Tagawa; Matteo Benelli; Francesca Demichelis
Journal:  J Clin Invest       Date:  2020-04-01       Impact factor: 14.808

9.  Cancer origins-genetics rules the day.

Authors:  Michael S Kareta; Julien Sage
Journal:  Science       Date:  2018-10-05       Impact factor: 47.728

Review 10.  Lineage plasticity in cancer: a shared pathway of therapeutic resistance.

Authors:  Álvaro Quintanal-Villalonga; Joseph M Chan; Helena A Yu; Dana Pe'er; Charles L Sawyers; Triparna Sen; Charles M Rudin
Journal:  Nat Rev Clin Oncol       Date:  2020-03-09       Impact factor: 66.675

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.